glp 1 agonist risks GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies GLP-1 Muscle Loss Explained |

To overcome this limitation, the pharmaceutical industry developed GLP-1 analogs, compounds designed to mimic the hormones action while extending its duration

DozioEVianelloEMalavazosAETacchiniLSchmitzGIacobellisGet alEpicardial adipose tissue GLP-1 receptor is associated with genes involved in fatty acid oxidation and white-to-brown fat differentiation: a target to modulate cardiovascular risk

Additional information Enhanced Digital Features To view enhanced digital features for this article go to Electronic supplementary material Below is the link to the electronic supplementary material

Osteoclast number on the surface of trabecular bone was observed by histological analysis, which demonstrated a significant decrease after 16 weeks of exendin-4 use in OVX rats (10)